Influence of dosing time of bazedoxifene in postmenopausal women with osteoporosis

Influence of dosing time of bazedoxifene in postmenopausal women with osteoporosis - Chronotherapy of bazedoxifene

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011412

Enrollment

Registered

2013-08-07

Start date

2013-08-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postmenopausal osteoporosis

Interventions

Morning-administration of bazedoxifene Evening-administration of bazedoxifene

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Outpatients Diagnosed postmenopausal osteoporosis Written informed consent

Exclusion criteria

Exclusion criteria: Treatment with bazedoxifene, raloxifene or bisphosphonate in the preceding 12 months Anticoagulant therapy Inpatients Current or previous thromboembolic disease Bedridden subjects Antiphospholipid antibody syndrome Possibility of pregnancy Pregnant or nursing women Hypersensitivity to bazedoxifene Severe hepatic impairment Severe renal dysfunction Other unsuitableness

Design outcomes

Primary

Measure	Time frame
Coagulation and fibrinolysis factors Bone metabolism markers	—

Secondary

Measure	Time frame
Development of thromboembolism and bone fracture Any other adverse effects Compliance	—

Countries

Japan

Contacts

Public ContactHitoshi Ando

Jichi Medical University Clinical Pharmacology

h-ando@jichi.ac.jp0285-58-7388

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026